Canada: B.C. Court Dismisses Proposed Class Action Against Generic Manufacturers Of Fentanyl Patch

On June 20, 2014, Justice Bracken of the British Columbia Supreme Court dismissed a proposed class action against two generic manufacturers of transdermal fentanyl patches following a summary trial, prior to the certification hearing (Player v. Janssen-Ortho Inc., 2014 BCSC 1122). In doing so, he considered the following issues:

  • Whether the matter was appropriate for summary trial;
  • The appropriate scope of evidence that may be considered in a pre-certification summary trial; and
  • The merits of the plaintiff's claim, including the extensive expert evidence filed by the parties.

He concluded that the evidence did not support any of the plaintiffs' claims, which purported to be founded on a range of legal principles, including negligent design, failure to warn, misrepresentation, breach of fiduciary duty and strict liability, as well as on alleged breaches of the Competition Act, the Food and Drugs Act, the Business Practices and Consumer Protecting Act, and the Sale of Goods Act.


The proposed class proceeding targeted several manufacturers of a form of painkiller, of which the active ingredient, fentanyl, is delivered by a patch applied directly to the patient's skin. The plaintiffs, who were suing on their own behalf and on behalf of the estates of their deceased spouses who were alleged to have overdosed on fentanyl, alleged that, due to design defects, the fentanyl patches can cause serious harm in ordinary use.

The plaintiff commenced the proposed class proceeding in September 2010 on behalf of all persons in British Columbia including their estates, who used fentanyl patches after December 20, 1991. The claim was subsequently expanded to cover all of Canada. The plaintiff moved for certification, while two of the defendants who manufacture generic versions of the fentanyl patch, Teva Canada Limited and Sandoz Canada Incorporated (the applicant defendants), applied for an order directing a summary trial of the claims against them. Following a sequencing hearing, Justice Bracken ordered that the summary trial could proceed prior to the certification hearing.

The basis for the applicant defendants' summary trial application was that they manufacture a different product from the other defendants. The evidence showed that fentanyl patches come in two types: (i) "matrix" drug-in-adhesive patches, where the drug is suspended in a semi-solid state within the adhesive patch, and (ii) "reservoir" style patches, which have a reservoir of liquid/gel fentanyl that is released into the patient's bloodstream through a rate-controlling membrane. The applicant defendants took the position that the claim is over-inclusive insofar as it fails to support allegations of harm with respect to the matrix-style patches manufactured by the applicant defendants, as opposed to the reservoir style used by the other defendants.

Scope of Inquiry in a Pre-Certification Summary Trial

As a preliminary matter, Justice Bracken considered whether the court should consider only those facts that relate to the representative plaintiffs or whether it should also consider facts relating to the class as a whole. He began by noting a significant difference between B.C. class actions law and that of other provinces: in most Canadian provinces a proposed class proceeding is treated as an individual action, but this is not so in British Columbia. Under B.C. law, a pre-certification proceeding cannot be dismissed solely on the basis that the representative plaintiff does not have a claim against any particular defendant. In Justice Bracken's view, it followed from this that, in a summary trial, the court can properly consider admissible evidence relating to the claims of the potential class members, including evidence from proposed class members and expert evidence that the products are defective in design and thus in breach of the duty of care to all class members.

Justice Bracken noted, however, that this is complicated in the context of the summary trial rule which allows the court to grant judgment in favour of any party, regardless of which party has brought the application. The court noted that while it could consider the evidence of proposed class members, it could not use this evidence to issue judgment in favour of the representative plaintiffs as the proposed class members were not parties to the action. Accordingly, the evidence relating to the proposed class was considered by Justice Bracken only in determining whether it would be unjust to decide the issues on the application. His Honour noted that if the representative plaintiffs failed to prove their claims, but there was evidence that the applicant defendants breached a duty of care to Canadian consumers, he would not issue judgment on the summary trial and would allow the claims to continue.

As it turned out, the plaintiffs did not adduce any direct evidence from the proposed class members (though they could have). Instead, they tried these alternative tactics:

  • Submitting affidavits from members of the plaintiffs' law firm who had spoken with proposed class members; and
  • Presenting evidence of adverse event reports submitted by consumers, health professionals, manufacturers and distributors to Health Canada and made available in an online database by Health Canada.

Neither of these approaches went down very well with the court. The affidavit evidence, being hearsay, was given minimal weight. The evidence from the Health Canada website was, as Justice Bracken noted, double hearsay. Not only that, it was unreliable and could not be used either as evidence of injuries caused by fentanyl patches or as evidence of risks associated with those products.

Suitability for Summary Trial

The British Columbia Supreme Court Civil Rules permit any party to apply to the court for judgment by way of summary trial, which involves evidence via affidavits and written materials rather than by viva voce testimony. A court may not grant judgment in a summary trial if the judge is unable to find the facts necessary to determine the issues or is of the opinion that it would be unjust to decide the issues summarily. The factors considered by the court in making this determination include the complexity of the matter and whether credibility is a critical factor in the determination of the dispute. Justice Bracken noted that in a summary trial all parties must come to the hearing "prepared to prove their claim, or defence" and as such the plaintiff cannot argue that the matter is unsuitable for summary disposition on the basis that they have not put forward sufficient evidence.

Appropriateness of Summary Trials in Class Proceedings

The plaintiffs argued that in the context of a proposed class proceeding, a summary trial was prima facie inappropriate for determining issues in the proceeding, raising a number of objections.

The plaintiffs argued that as a pre-certification decision would only bind the representative plaintiffs (and not members of the proposed class), a summary trial was not efficient given that another member of the proposed class would simply step forward to pursue the claim on behalf of the class. Justice Bracken held that this concern, in itself, was not sufficient to find that a summary trial was inappropriate because the application concerned issues common to all class members (i.e., whether the applicant defendants were in breach of any duty in law to users of their product) and not just the representative plaintiffs. He further held that if the evidence is insufficient to support the action, then "the consequences associated with involvement in an extensive and expensive class action are very serious":

As stated in Kowch at para. 14, "[i]t is not a principle of class action law that weeds should be allowed to ripen and grow, instead of being nipped in the bud."

Further, if the matter has no merit, allowing it to continue to certification will undoubtedly cause prejudice to Teva and Sandoz. Where the court can find the necessary facts through the summary process, it promotes efficiency to issue judgment at the pre-certification stage.

Two Key Issues

Justice Bracken next considered whether the complexity of the case or evidence made it unsuitable for summary trial. Justice Bracken held that while the evidentiary record was extensive, the two key issues were relatively straightforward:

  • Whether there was evidence to connect the applicant defendants' product to the deaths of the plaintiffs, and
  • Whether there was sufficient evidence to establish the product was defectively designed.

On the first issue, there was no evidence to connect the applicant defendants' products to the death of one plaintiff as it was admitted that he did not use their products. Regarding the other plaintiff, there was insufficient evidence to prove that he used a fentanyl patch manufactured by the applicant defendants. In addition, Justice Bracken found the plaintiffs did not put forward any admissible evidence establishing fentanyl as a cause of his death.

On the second issue (defective design), Justice Bracken found that he could not give sufficient weight to the evidence of the plaintiffs' expert as she was not qualified to give an opinion on some aspects of the case, she chose to ignore evidence that contradicted her opinion and had taken the role of an advocate contrary to the rules on the admissibility of expert opinion evidence. In any event, at best, her evidence on defective design was that there is another design or designs that might be safer. Accordingly, there was no credible evidence to support the plaintiffs' claim nor was the case too complex to be decided on summary trial.

Justice Bracken noted that there had been examinations for discovery and cross-examinations and therefore the plaintiffs had a full opportunity to present evidence to support their claims. The evidence that had been presented allowed for a full appreciation of the facts essential to the determination of the plaintiffs' action:

Class actions are a powerful tool. They allow an action to proceed where an individual plaintiff would find the cost of an action prohibitive as well as in actions where the research and investigation is not within the ability of a single plaintiff. However, it is not a tool where simply making an allegation against a defendant or group of defendants is sufficient. There must be evidence to warrant the expense of a full trial.

Findings on the Merits

After an extensive review of the evidence, Justice Bracken found that the evidence did not support any of the plaintiffs' claims.


The onus is on a plaintiff to show that a product as designed was not reasonably safe as there was a substantial likelihood of harm and it was feasible to design the product in a safer manner. Justice Bracken found that the applicant defendants complied with appropriate regulatory standards and accepted the evidence of the defendants' experts on the utility and usefulness of their products as well as on the lack of availability of a suitable alternative. His Honour concluded that there was no satisfactory evidence to show that there was a safer alternative design or that an alternate design of the fentanyl patches was available and could have been used but for the negligence of the applicant defendants.

Failure to Warn

The plaintiffs alleged that the applicant defendants failed to provide adequate warning to consumers of the dangers associated with the use of fentanyl. Based on his review of the product monograph (which was identical to the product monograph approved by Health Canada for the innovator drug) and the expert evidence, Justice Bracken concluded that the product monograph contained clear, accurate and understandable warnings such that the applicant defendants were not liable for failure to warn.

Additional Grounds of Liability

Having found no negligence or failure to warn, Justice Bracken dealt summarily with the additional claims advanced by the plaintiffs finding: there was no misrepresentation of facts in the product monograph; there was no evidence of unlawful, unfair or deceptive trade practices in contravention of the Competition Act nor was there any evidence of a causal connection between the applicants' fentanyl patches and any loss or damage to the plaintiffs; there was no evidence to support breach of consumer protection legislation or any express or implied warranty under the Sale of Goods Act; there was no evidence to support a fiduciary relationship and a breach of fiduciary duty by the applicant defendants; and there was no claim for strict liability as courts in Canada have rejected the doctrine of strict liability in products liability cases.

The Ruling

Accordingly, the action was dismissed as against the applicant defendants.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.